Student or educator? Sign up with your school email and get 6 months of Pro free.

The DOI matches its Crossref record; 90 of the 90 references it cites were found in a registry or an index.

Sarcopenic obesity

Polyzos, Stergios A., Margioris, Andrew N. · 2018 · Hormones

Abstract

Sarcopenic obesity, a chronic condition, is today a major public health problem with increasing prevalence worldwide, which is due to progressively aging populations, the increasing prevalence of obesity, and the changes in lifestyle during the last several decades. Patients usually present to healthcare facilities for obesity and related comorbidities (type 2 diabetes mellitus, non-alcoholic fatty liver disease, dyslipidemia, hypertension, and cardiovascular disease) or for non-specific symptoms related to sarcopenia per se (e.g., fatigue, weakness, and frailty). Because of the non-specificity of the symptoms, sarcopenic obesity remains largely unsuspected and undiagnosed. The pathogenesis of sarcopenic obesity is multifactorial. There is interplay between aging, sedentary lifestyle, and unhealthy dietary habits, and insulin resistance, inflammation, and oxidative stress, resulting in a quantitative and qualitative decline in muscle mass and an increase in fat mass. Myokines, including myostatin and irisin, and adipokines play a prominent role in the pathogenesis of sarcopenic obesity. It has been suggested that a number of disorders affecting metabolism, physical capacity, and quality of life may be attributed to sarcopenic obesity, although it is not as yet established whether sarcopenia and obesity act synergistically. There is to date no approved pharmacological treatment for sarcopenic obesity. The cornerstones of its management are weight loss and adequate protein intake combined with exercise, the latter in order to reduce the loss of muscle mass observed during weight loss following diet unpaired with exercise. A consensus on the definition of sarcopenic obesity is considered essential to facilitate the performance of mechanistic studies and clinical trials aimed at deepening our knowledge, thus enabling improved management of affected individuals in the near future.

Overview

Integrity signals

Registry

Crossref · 10.1007/s42000-018-0049-x

Cites

90 of 90 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 90 references

Research works printed but not linked: 2

  1. Polyzos SA, Kountouras J, Mantzoros CS (2017) Adipose tissue, obesity and non-alcoholic fatty liver disease. Minerva Endocrinol 42:92–108
  2. An KO, Kim J (2016) Association of sarcopenia and obesity with multimorbidity in Korean adults: a nationwide cross-sectional study. J Am Med Dir Assoc 17(960):e961–e967

Cited by

See all 212

Metadata

Authors
Polyzos, S. A., & Margioris, A. N.
Affiliations
University of Crete (GR)
Venue
Hormones
Published
2018-07-16
Volume
17
Issue
3
Pages
321-331
ISSN
  • 1109-3099 (ISSN-L)
  • 2520-8721
OpenAlex
W4234165494
Cited by
212
References
90
Citations by year
2026: 17 · 2025: 29 · 2024: 22 · 2023: 31 · 2022: 36 · 2021: 35 · 2020: 24 · 2019: 17 · 2018: 1
FWCI
2.53
Type
journal article
Language
en
Open access
closed
Licence
www.springer.com/tdm (tdm)
Locations
  • HORMONES (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Physiology (medical) › Nutrition and Health in Aging
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Muscle Physiology and Disorders
  • Health Sciences › Medicine › Physiology (medical) › Body Composition Measurement Techniques
Keywords
sarcopenic obesity, sarcopenia, obesity, muscle mass loss, fat mass, aging, sedentary lifestyle, insulin resistance, inflammation, oxidative stress, myostatin, irisin, adipokines, myokines, weight loss, protein intake, physical activity, frailty, type 2 diabetes, non-alcoholic fatty liver disease, cardiovascular disease, dyslipidemia, hypertension
MeSH terms
Aging, Humans, Life Style, Obesity, Sarcopenia

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Sarcopenic obesity. https://app.cochat.ai/papers/10.1007/s42000-018-0049-x
The paper
Polyzos, S. A., & Margioris, A. N. (2018). Sarcopenic obesity. Hormones. https://doi.org/10.1007/s42000-018-0049-x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.